Key facts
- It has raised $1.1M; the latest was Later Stage VC ($750K) in Dec 2025.
- Notable investors include US National Science Foundation, MassChallenge, Venture Kick, Venture (Switzerland), Community Development Venture Capital Alliance — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Beken Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Beken Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beken Bio
Developer of diagnostic technology designed to enable early cancer detection. The company specializes in identifying pre-symptomatic cancer biomarkers through a proprietary three-dimensional cell growth platform and AI-driven protein analysis to detect cancer at an early stage, enabling clinicians to detect cancer early and improve patient survival outcomes.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2014
- Employees
- 4
- Website
- beken.bio/
- Ownership
- Privately Held (backing)
Beken Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beken Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beken Bio in its N-PORT filings yet. We sweep new filings monthly.